The "Technology for the next Generation" prize is meant to support young scientists and startups who are doing research for the health of the next generation.
The analysis of large data set ("big data") is getting crucial. Here, we see an interesting overlap of these fields with computer sciences. For this reason, we wish to support scientists and startups in this field. However, this is just one aspect where we think we could be supportive.
Are you working on your Bachelor, Master or PhD thesis in one of the mentioned areas or do you need support? Or are you part of a startup in this field? Apply now! Or send us a Mail if you have any questions.
Application deadline: September 22, 2023
Award: Mid November 2023
The prize is valued at CHF 10'542.00. 60% of the prize is paid out and 40% provided as IT service. With IT service we think of support with data analysis, statistical studies with R, programming in Python, database cluster and computing power, advice in choosing hard- and software.
With the first-time foundation of the Technology for the Next Generation prize, we want to break new ground as part of our social commitment and have tried to choose a goal with whom a large part of our employees, customers, and society can identify. Especially as a father of three healthy children, we want to take full responsibility for our and future generations and are convinced that IT can be of great help in this area as well.
Christian Hensel, CEO
During my time in the management of SFL, a Basel-based, leading consultancy providing integrated solutions to pharma, biotech and medtech companies for global and local activities, I appreciated Hejuba for their solution-oriented support of our international employees and equally for their future-oriented and resource-efficient approaches and discussions. Accordingly, the "Technology for the next Generation" – Award reflects perfectly on the philosophy and societal responsibility of the founders of Hejuba, and I am proud to support this activity.
Walter Fürst, Co-Founder SFL-Services
We have been happy to receive professional support for all our needs through HEJUBA over the last two years and the fact that they actively support our target group - Scientific founders makes us doubly happy to work with them.
Douglas Haggstrom, Manager INCATE
Elena Börlin and her team at SeFit were the winners in 2023. SeFit aims to make Virtual Reality more accessible for therapists, thereby simplifying exposure therapy. Exposure therapy can be used for various purposes, such as treating anxiety disorders. The goal is now to combine VR headsets with real-life recorded scenes, an app, and a web application, along with digital biomarkers, to assist people suffering from sensory filter deficits. Sensory filter deficit is particularly known in the context of ADHD, Asperger's, and migraines, but there are other diagnoses that are also affected.
The 2022 winners are Aukera Therapeutics with "Unleashing the therapeutic potential of mTOR inhibition". Cell growth and proliferation (increase in cell number) in the human body are controlled by the protein mTOR. mTOR works in two different forms: mTOR complex 1 and mTOR complex 2. Cancer cells are generally characterized by increased cell growth and proliferation, and approximately 70 % of all cancers show increased mTOR complex 1 activity. In addition, certain neurological disorders show upregulation of mTOR complex 1 signaling. Aukera Therapeutics is developing a unique class of drugs that can selectively and safely reduce the activity of mTOR complex 1.
This year we also gave Round Table Antibiotics an honorary award in recognition of their social commitment.
This year's winner is Daniel Hauke with his research on paranoid schizophrenia. We are proud to support Daniel in this area by developing an app for early diagnosis and faster medication discovery.
Schizophrenia is a serious psychiatric illness that affects millions of people worldwide (World Health Organization). Persecution thoughts are a particularly common symptom that occurs in around 70% of all first-time patients (Freeman & Garety, 2014) and is a particularly stressful symptom for those affected. At present, however, the treatment of such symptoms is tedious and it can take several months to find the right medicament, as there are no valid predictors for the success of various drugs. The goal of our research is to develop computer-aided tests for clinicians that help predict the success of medication or potential side effects, in order to significantly shorten the time it takes to find an effective medication for a patient and to adapt the medical treatment to the individual patient. We are also testing whether these computer-assisted tests can be used beforehand to predict whether patients who are at increased risk of schizophrenia will actually get it.
The winners of the "Technology for the next Generation" prize 2019 are Asier González Seviné and Stefan Imseng from the Biozentrum, University of Basel with their project "Unleashing the clinical benefit of selective mTORC1 inhibition". To the website